KCNQ2/3 Channel Activation (SF0034 / RL-81)
Small-molecule activators that shift the voltage-dependence of Kv7.2/3 (KCNQ2/3) channels to more negative voltages, restoring their natural brake on neuronal excitability
Preclinical: animal (in vivo) evidence, not yet studied in humans
How it works
Preclinical tool compounds developed in the Tzounopoulos lab (SF0034, then the more specific RL-81) prevented or mitigated noise-induced tinnitus in mice, including when given up to a week after noise trauma. These are distinct research compounds from clinical Kv7-opener drugs such as XEN1101 (Azetukalner), Opakalim, and Bimokalner already tracked in the Therapy Pipeline for epilepsy, depression, or hearing indications, but they act on the same channel class, making those clinical Kv7 openers a natural (not yet tested) candidate for tinnitus.
This describes the treatment concept as reported in the cited research: a scientific mechanism, not a guarantee of clinical availability.
Evidence (2)
Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.
The Journal of neuroscience : the official journal of the Society for Neuroscience · 2015
A more potent, more selective KCNQ2/3 activator (SF0034) prevented tinnitus development in mice, and was a safer anticonvulsant than the FDA-approved retigabine.
Transient Delivery of a KCNQ2/3-Specific Channel Activator 1 Week After Noise Trauma Mitigates Noise-Induced Tinnitus.
Journal of the Association for Research in Otolaryngology : JARO · 2021
Even started a week after noise trauma, well after the injury, not just immediately, a specific KCNQ2/3 activator (RL-81) still reduced the development of tinnitus in mice.